Cargando…

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer

BACKGROUND: Biomarkers for metastatic castration-resistant prostatic cancer (mCRPC) are an unmet medical need. METHODS: The prognostic and predictive value for survival and response to salvage hormonal therapy (SHT) of baseline testosterone level (TL) was analysed in a cohort of 101 mCRPC patients p...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Liaño, A G, Reig, O, Mellado, B, Martin, C, Rull, E U, Maroto, J P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007243/ https://www.ncbi.nlm.nih.gov/pubmed/24722180 http://dx.doi.org/10.1038/bjc.2014.189

Ejemplares similares

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
por: Chowdhury, Simon, et al.
Publicado: (2020)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Miura, Noriyoshi, et al.
Publicado: (2020)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
por: Li, Jun-Hong, et al.
Publicado: (2023)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

“Prostate telocytes change their phenotype in response to castration or testosterone replacement”
por: Felisbino, Sérgio Luis, et al.
Publicado: (2019)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
por: Yamashita, Shimpei, et al.
Publicado: (2016)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer
por: Bremmer, Felix, et al.
Publicado: (2018)

Discordance between testosterone measurement methods in castrated prostate cancer patients
por: Rouleau, Mélanie, et al.
Publicado: (2019)

Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
por: Ozyigit, Gokhan, et al.
Publicado: (2019)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
por: Mak, Blossom, et al.
Publicado: (2022)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2015)

Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
por: Poon, Darren M.C., et al.
Publicado: (2015)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer
por: Moses, Marcus, et al.
Publicado: (2020)

Correction: Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2017)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
por: Chang, Li-Wen, et al.
Publicado: (2021)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison
por: Zheng, Haofeng, et al.
Publicado: (2017)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy
por: Zhao, Jinge, et al.
Publicado: (2017)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
por: Pu, Yeong-Shiau, et al.
Publicado: (2022)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n5hqcf52dgoohjejfp00n78s9i